hepatocellular carcinoma common type primary liver cancer adults currently common cause death people hcc third leading cause cancerrelated deaths development hcc attributed fibrosis cirrhosis occur setting chronic liver injury inflammation latter closely linked chronic viral hepatitis infection hepatitis b c exposure toxins alcohol aflatoxin pyrrolizidine certain diseases hemochromatosis alpha deficiency markedly increase risk developing hcc metabolic syndrome nash also increasingly recognized risk factors cancer treatment prognosis hcc vary depending specifics tumor histology size far cancer spread overall health vast majority hcc cases lowest survival rates treatment occur asia subsaharan africa countries hepatitis b infection endemic many infected birth incidence hcc united states developing countries increasing due increase hepatitis c virus infections three times common males females unknown cases hcc occur people already signs symptoms chronic liver disease may present worsening symptoms without symptoms time cancer detection hcc may present nonspecific symptoms abdominal pain nausea vomiting feeling symptoms closely associated liver disease include yellow skin also called jaundice abdominal swelling due fluid abdominal cavity easy bruising blood clotting abnormalities loss appetite unintentional weight loss abdominal pain nausea vomiting feeling since hcc mostly occurs people cirrhosis liver risk factors generally include factors cause chronic liver disease may lead cirrhosis still certain risk factors highly associated hcc others example heavy alcohol consumption estimated cause cirrhosis vast majority hcc occurs cirrhosis attributed viral hepatitis although may recognized risk factors include significance risk factors varies globally regions hepatitis b infection endemic southeast china hepatitis b predominant populations largely protected hepatitis b vaccination united states hcc often linked causes cirrhosis chronic hepatitis c obesity excessive alcohol certain benign liver tumors hepatocellular adenoma may sometimes associated coexisting malignant hcc evidence limited true incidence malignancy associated benign adenomas however size hepatic adenoma considered correspond risk malignancy larger tumors may surgically removed certain subtypes adenoma particularly Î²catenin activation mutation particularly associated increased risk chronic liver disease rare children adolescents however congenital liver disorders associated increased chance developing specifically children biliary atresia infantile cholestasis glycogenstorage diseases cirrhotic diseases liver predisposed developing hcc childhoodcitation needed young adults afflicted rare fibrolamellar variant hepatocellular carcinoma may none typical risk factors cirrhosis risk hepatocellular carcinoma type diabetics greater times nondiabetic risk depending duration diabetes treatment suspected contributor increased risk circulating insulin concentration diabetics poor insulin control treatments elevate insulin output states contribute higher circulating insulin concentration show far greater risk hepatocellular carcinoma diabetics treatments reduce circulating insulin note diabetics engage tight insulin control keeping elevated show risk levels low enough indistinguishable general phenomenon thus isolated diabetes mellitus type since poor insulin regulation also found conditions metabolic syndrome specifically evidence nonalcoholic fatty liver disease nafld present evidence greater risk exists claims anabolic steroid abusers greater theorized due insulin igf evidence confirmed anabolic steroid users likely benign hepatocellular adenomas transform dangerous hepatocellular hepatocellular carcinoma like cancer develops epigenetic alterations mutations affecting cellular machinery cause cell replicate higher rate andor result cell avoiding particular chronic infections hepatitis b andor c aid development hepatocellular carcinoma repeatedly causing bodys immune system attack liver cells infected virus others merely activated immunesystem inflammatory cells release free radicals reactive oxygen species nitric oxide reactive species turn cause dna damage lead carcinogenic gene reactive oxygen species also cause epigenetic alterations sites dna constant cycle damage followed repair lead mistakes repair turn lead carcinogenesis hypothesis applicable present hepatitis c chronic hepatitis c causes hcc stage cirrhosis chronic hepatitis b however integration viral genome infected cells directly induce noncirrhotic liver develop hcc alternatively repeated consumption large amounts ethanol similar effect toxin aflatoxin certain aspergillus species fungi carcinogen aids carcinogenesis hepatocellular cancer building liver combined high prevalence rates aflatoxin hepatitis b settings china west africa led relatively high rates hepatocellular carcinoma regions viral hepatitides hepatitis potential become chronic infection thus related methods diagnosis hcc evolved improvement medical imaging evaluation asymptomatic patients symptoms liver disease involves blood testing imaging evaluation historically biopsy tumor required prove hcc diagnosis however imaging especially mri findings may conclusive enough without histopathologic hcc remains associated high mortality rate part initial diagnosis commonly occurs advanced stage disease cancers outcomes significantly improved treatment initiated earlier disease process since vast majority hcc cases occur people certain chronic liver diseases especially cirrhosis liver screening commonly advocated population specific screening guidelines continue evolve time evidence clinical impact becomes available united states commonly observed guidelines published american association study liver diseasesaasld recommends ultrasound screenings every six months people cirrhosis without measurement blood levels tumor marker alphafetoprotein elevated levels afp associated active hcc disease though reliability inconsistent levels sensitivity specificity however levels sensitivity specificity ultrasound hcc often appears small hypoechoic lesion poorly defined margins coarse irregular internal echoes tumor grows sometimes appear heterogeneous fibrosis fatty change calcifications heterogeneity look similar cirrhosis surrounding liver parenchyma systematic review found sensitivity ci specificity ci compared pathologic examination explanted resected liver reference standard sensitivity increases afp controversy remains effective screening protocols example data support decreased mortality related screening people hepatitis b infection aasld notes randomized trials screening western populations cirrhosis secondary chronic hepatitis c fatty liver disease thus controversy surrounding whether surveillance truly leads reduction mortality population patients cirrhosis person higher suspicion hcc exists person symptoms abnormal blood tests ie alphafetoprotein desgamma carboxyprothrombin evaluation requires imaging liver ct mri scans optimally scans performed intravenous contrast multiple phases hepatic perfusion improve detection accurate classification liver lesions interpreting radiologist due characteristic blood flow pattern hcc tumors specific perfusion pattern detected liver lesion may conclusively detect hcc tumor alternatively scan may detect indeterminate lesion evaluation may performed obtaining physical sample ultrasound ct scan mri may used evaluate liver hcc ct mri hcc three distinct patterns growthcitation needed systematic review ct diagnosis found sensitivity ci specificity ci compared pathologic examination explanted resected liver reference standard triplephase helical ct sensitivity higher data confirmed autopsy however mri advantage delivering highresolution images liver without ionizing radiation hcc appears highintensity pattern images lowintensity pattern images advantage mri improved sensitivity specificity compared ultrasound ct cirrhotic patients difficult differentiate hcc regenerative nodules systematic review found sensitivity ci specificity ci compared pathologic examination explanted resected liver reference sensitivity increased gadolinium contrastenhanced diffusionweighted imaging combined mri sensitive specific liver image reporting data system lirads classification system reporting liver lesions detected ct mri radiologists use standardized system report suspicious lesions provide estimated likelihood malignancy categories range lirads lr order concern biopsy needed confirm diagnosis hcc certain imaging criteria macroscopically liver cancer appears nodular infiltrative tumor nodular type may solitary large mass multiple developed complication cirrhosis tumor nodules round oval gray green tumor produces bile well circumscribed encapsulated diffuse type poorly circumscribed infiltrates portal veins hepatic veins microscopically four architectural cytological types patterns hepatocellular carcinoma fibrolamellar pseudoglandular adenoid pleomorphic giant cell clear cell welldifferentiated forms tumor cells resemble hepatocytes form trabeculae cords nests may contain bile pigment cytoplasm poorly differentiated forms malignant epithelial cells discohesive pleomorphic anaplastic giant tumor scant stroma central necrosis poor fifth form lymphoepithelioma like hepatocellular carcinoma also welldifferentiated hcc moderately differentiated hcc poorly differentiated hcc bclc staging system prognosis hcc affected staging tumor livers function due effects liver number staging classifications hcc available however due unique nature carcinoma fully encompass features affect categorization hcc classification system incorporate tumor size number presence vascular invasion extrahepatic spread liver function levels serum bilirubin albumin presence ascites portal hypertension general health status patient defined ecog classification presence staging classification systems available barcelona clinic liver cancer staging classification encompasses characteristics staging classification used select people important features guide treatment include mri best imaging method detect presence tumor capsule common sites metastasis lung abdominal lymph nodes since hepatitis b c main causes hepatocellular carcinoma prevention infection key prevent hcc thus childhood vaccination hepatitis b may reduce risk liver cancer case patients cirrhosis alcohol consumption avoided also screening hemochromatosis may beneficial whether screening chronic liver disease hcc improves outcomes treatment hepatocellular carcinoma varies stage disease persons likelihood tolerate surgery availability liver transplant locoregional therapy also referred liverdirected therapy refers one several minimallyinvasive treatment techniques focally target hcc within liver procedures alternatives surgery may considered combination strategies later liver generally treatment procedures performed interventional radiologists surgeons coordination medical oncologist locoregional therapy may refer either percutaneous therapies eg cryoablation arterial catheterbased therapies chemoembolization radioembolizationcitation needed surgical removal tumor associated better cancer prognosis patients suitable surgical resection due extent disease poor liver surgery considered entire tumor safely removed preserving sufficient functional liver maintain normal physiology thus preoperative imaging assessment critical determine extent hcc estimate amount residual liver remaining surgery maintain liver function residual liver volume exceed total liver volume noncirrhotic liver greater cirrhotic surgery diseased cirrhotic livers generally associated higher morbidity mortality overall recurrence rate resection singapore liver cancer recurrence score used estimate risk recurrence liver transplantation replacing diseased liver cadaveric living donor liver plays increasing role treatment hcc although outcomes following liver transplant initially poor survival outcomes significantly improved improvement surgical techniques adoption milan criteria us transplantation centers expanded shanghai criteria china resulted overall survival diseasefree survival rates similar achieved using milan studies late obtained higher survival rates ranging risks liver transplantation extend beyond risk procedure immunosuppressive medication required surgery prevent rejection donor liver also impairs bodys natural ability combat dysfunctional cells tumor spread undetected outside liver transplant medication effectively increases rate disease progression decreases survival mind liver transplant curative approach patients advanced hcc without extrahepatic fact among patients compensated cirrhosis transplantation associated improved survival compared hepatectomy instead significantly patient selection considered major key disease spread beyond liver systemic therapy may consideration sorafenib oral multikinase inhibitor first systemic agent approved firstline treatment advanced trials found modest improvement overall survival months vs months months vs common side effects sorafenib include handfoot skin reaction sorafenib thought work blocking growth tumor cells new blood vessels numerous molecular targeted drugs tested alternative first secondline treatments advanced host additional targeted therapies immune checkpoint inhibitors found effective disease instance recent phase iii trial imbrave combination atezolizumab bevacizumab found improve overall progressionfree survival compared sorafenib tremelimumab imjudo approved medical use united states october indicated combination durvalumab treatment adults unresectable hepatocellular usual outcome poor hepatocellular carcinomas removed completely using surgery cancer completely removed disease usually deadly within verification partially due late presentation tumors also lack medical expertise facilities regions high hcc prevalence however survival vary occasionally people survive much longer months prognosis metastatic unresectable hcc improved due approval sorafenib advanced hcccitation needed hcc one common tumors worldwide epidemiology hcc exhibits two main patterns one north america western europe another nonwestern countries subsaharan africa central southeast asia amazon basin males affected females usually common ages hepatocellular carcinoma causes deaths worldwide per half china parts world subsaharan africa southeast asia hcc common cancer generally affecting men women age onset late teens variability part due different patterns hepatitis b hepatitis c transmission different populations infection around birth predispose earlier cancers people infected later time hepatitis b infection development hcc years even decades diagnosis hcc death average survival period months according one chinese study months median survival time subsaharan africa according mansons textbook tropical diseases hcc one deadliest cancers china chronic hepatitis b found cases japan chronic hepatitis c associated hcc cases foods infected aspergillus flavus especially peanuts corns stored prolonged wet seasons produces aflatoxins pose another risk factor common malignant tumors liver represent metastases spread tumors originate elsewhere among cancers originate liver tissue hcc common primary liver cancer united states us surveillance epidemiology end results database program shows hcc accounts cases liver screening programs place highrisk persons chronic liver disease hcc often discovered much earlier western countries developing regions subsaharan africacitation needed acute chronic hepatic porphyrias acute intermittent porphyria porphyria cutanea tarda hereditary coproporphyria variegate porphyria tyrosinemia type risk factors hepatocellular carcinoma diagnosis acute hepatic porphyria aip hcp vp sought patients hcc without typical risk factors hepatitis b c alcoholic liver cirrhosis hemochromatosis active latent genetic carriers acute hepatic porphyrias risk cancer although latent genetic carriers developed cancer later age classic symptoms patients acute hepatic porphyrias monitored hcccitation needed incidence hcc relatively lower western hemisphere eastern asia however despite statistics low diagnosis hcc increased since continuing increase making one rising causes death due cancer common risk factor hcc hepatitis c along health mipsagargin orphan drug designation treatment chemotherapy thapsigarginbased prodrug cytotoxic activity used reduce blood flow tumor treatment results phase trial recommended firstinclass psmatargeted prodrug move clinical current research includes search genes disregulated hcc antiheparanase protein noncoding predictive similar research yielding results various malignant diseases hoped identifying aberrant genes resultant proteins could lead identification pharmacological interventions development threedimensional culture methods provides new approach preclinical studies cancer therapy using patientderived organoids miniaturized organoid avatars patients tumor recapitulate several features original tumor rendering attractive model drugsensitivity testing precision medicine hcc types primary liver furthermore hcc occurs patients liver disease biomarker named sixmirna signature allows effective treatment patients hcc able predict recurrence prospective study found increased hepatocellular cancer risk associated higher levels major circulating bile acids measured people several years prior tumor another study using mouse model found dysregulated hepatic bile acids collaboratively promote liver oncolytic virus orphan drug designation condition undergoing clinical hepcortespenlisimutl oral cancer vaccine also us fda orphan drug designation immunitor inc completed phase ii trial published randomized trial people advanced hcc showed benefit combination everolimus httpsenwikipediaorgwikihepatocellularcarcinoma